TY - JOUR
T1 - I tumori gliali. La nostra esperienza radioterapica
AU - Arcicasa, M.
AU - Roncadin, M.
AU - Bortolus, R.
AU - Tortorici, G.
AU - Covezzi, E.
AU - Bidoli, E.
AU - Bassignano, G.
AU - Passadore, P.
AU - Lucci, B.
PY - 1997
Y1 - 1997
N2 - From 1978 to 1992, 135 consecutive patients with high grade glioma were treated at the Radiotherapy Department of Pordenone General Hospital. The patients were divided into 4 group (on the basis of the time of diagnosis): Group I, surgery if feasible followed by radiotherapy to the brain to a total dose of 34 Gy in 4 fractions, VCR (2 mg i.v.) and BCNU (80 mg/m2i.v.) repeated every 6 weeks; Group II, surgery if feasible and radiotherapy with the same schedule as Group I plus VP16 (75 mg/m2 i.v.) every 3 weeks and BCNU(50 mg/m2 i.v.) every 6 weeks; Group III, surgery if feasible and radiotherapy given to the brain to a total dose of 60 Gy in 30 fractions over 6 weeks plus VCR (2 mg i.v.), BCNU (50 mg/m2) and CDDP (15 mg/m2 i.v.) every 6 weeks; Group IV, after surgery when feasible, radiotherapy with the same schedule as Group III plus BCNU (40 mg/m2) and CDDP (40 mg/m2) given for 3 days in continues, simultaneous infusion, every 6 weeks. On April 30, 1996, in Group I, 28 patients had stable disease (SD) and 2 patients had disease progression. The median survival time was 9 months (range 1-18). In Group II there were 22 SDs. The median survival time was 6 months (range 2-16). In Group III there were 29 SDs and 14 partial remissions. The median survival time was 13 months (range 3-112,5+). In Group IV there were 34 SDs and 6 partial remissions. The median survival time was 13,5 months (range 3-92+). In general, the group of patients treated with radical or subtotal surgery and the patients included in neurological classes I and II, with performance status ≤ 70, and younger than 45 years had a longer survival. In our experience, the patients with a diagnosis of grade III and IV glioma included in the Groups III and IV had a longer survival than those in Groups I and II. None of the patients experienced severe toxicity from the treatment.
AB - From 1978 to 1992, 135 consecutive patients with high grade glioma were treated at the Radiotherapy Department of Pordenone General Hospital. The patients were divided into 4 group (on the basis of the time of diagnosis): Group I, surgery if feasible followed by radiotherapy to the brain to a total dose of 34 Gy in 4 fractions, VCR (2 mg i.v.) and BCNU (80 mg/m2i.v.) repeated every 6 weeks; Group II, surgery if feasible and radiotherapy with the same schedule as Group I plus VP16 (75 mg/m2 i.v.) every 3 weeks and BCNU(50 mg/m2 i.v.) every 6 weeks; Group III, surgery if feasible and radiotherapy given to the brain to a total dose of 60 Gy in 30 fractions over 6 weeks plus VCR (2 mg i.v.), BCNU (50 mg/m2) and CDDP (15 mg/m2 i.v.) every 6 weeks; Group IV, after surgery when feasible, radiotherapy with the same schedule as Group III plus BCNU (40 mg/m2) and CDDP (40 mg/m2) given for 3 days in continues, simultaneous infusion, every 6 weeks. On April 30, 1996, in Group I, 28 patients had stable disease (SD) and 2 patients had disease progression. The median survival time was 9 months (range 1-18). In Group II there were 22 SDs. The median survival time was 6 months (range 2-16). In Group III there were 29 SDs and 14 partial remissions. The median survival time was 13 months (range 3-112,5+). In Group IV there were 34 SDs and 6 partial remissions. The median survival time was 13,5 months (range 3-92+). In general, the group of patients treated with radical or subtotal surgery and the patients included in neurological classes I and II, with performance status ≤ 70, and younger than 45 years had a longer survival. In our experience, the patients with a diagnosis of grade III and IV glioma included in the Groups III and IV had a longer survival than those in Groups I and II. None of the patients experienced severe toxicity from the treatment.
KW - Malignant gliomas
KW - Radio-chemotherapeutic treatment
UR - http://www.scopus.com/inward/record.url?scp=0030983801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030983801&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0030983801
VL - 43
SP - 23
EP - 30
JO - Rivista Italiana di Neurobiologia
JF - Rivista Italiana di Neurobiologia
SN - 0035-6336
IS - 1
ER -